Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Janux Therapeutics Inc JANX

Healthcare Biotechnology
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:JANX)

Janux Therapeutics Announces Proposed Public Offering

Business Wire 23 hours ago

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Business Wire 1 day ago

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Business Wire 9 days ago

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Business Wire November 6, 2024

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Business Wire August 7, 2024

Janux Therapeutics Announces Updates to Board of Directors

Business Wire July 22, 2024

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Business Wire May 7, 2024

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Business Wire March 8, 2024

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Business Wire February 29, 2024
View More News ››

Opinion & Analysis (NDAQ:JANX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:JANX)

$JANX Climbs, $MYNZ Gains Momentum

$JANX surges 48.8% to $59.86 on investor confidence in its cancer immunotherapy advancements. Similarly, $MYNZ’s rebound post-split...
IronFocus77 - 6 hours ago

Janux Therapeutics, Inc. (NASDAQ:JANX): A Promising Biopharm

http://beyondspx.com/2024/07/31/janux-therapeutics-inc-nasdaqjanx-a-promising-biopharmaceutical-company-developing-innovative-tumor...
MikeTester - August 2, 2024

Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings

Just In: $JANX Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings | BenzingaU.S. stocks traded mixed toward the end of trading...
whytestocks - February 27, 2024

Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers

News; $JANX Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving...
whytestocks - February 27, 2024

Biotech Headliners

News; $JANX Biotech Headliners2024-02-27 09:06:36 ET DENVER, Colo., Feb 27, 2024 ( 247marketnews.com )- The following companies are...
whytestocks - February 27, 2024
View more Bullboard ››

Tenet Fintech Group Inc.

Tenet Fintech Group Inc.

Tenet Fintech Group Inc. is the parent company of a group of innovative financial technology (Fintech) and artificial ...
View More »